Secukinumab Efficacy and Safety Study in Patients With Rheumatoid Arthritis and Inadequate Response to Anti-TNFα Agents.
Status: | Completed |
---|---|
Conditions: | Arthritis, Rheumatoid Arthritis |
Therapuetic Areas: | Rheumatology |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 4/21/2016 |
Start Date: | October 2012 |
End Date: | May 2015 |
A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate the Efficacy at 24 Weeks and to Assess the Long Term Efficacy, Safety, Tolerability and Usability up to 5 Years in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Anti-TNFα Agents
This study will provide efficacy and safety data of the secukinumab pre-filled syringe (PFS)
for subcutaneous self-administration in patients with active rheumatoid arthritis who are
intolerant to or have had an inadequate response to anti-TNF-α agents.
for subcutaneous self-administration in patients with active rheumatoid arthritis who are
intolerant to or have had an inadequate response to anti-TNF-α agents.
Inclusion Criteria: • Presence of Rheumatoid Arthritis classified by ACR 2010 revised
criteria for at least 3 months •Disease activity defined by ≥6 tender joints out of 68 and
≥ 6 swollen joints out of 66 at baseline and with: Either Anti-CCP antibodies positive OR
Rheumatoid Factor positive AND WITH Either hsCRP ≥ 10 mg/L OR ESR ≥28 mm/1st hr •Intake of
at least one anti-TNF-α agent such as etanercept, adalimumab, infliximab, certolizumab or
golimumab for at least 3 months before entering the study and to have experienced an
inadequate response to treatment or to have been intolerant to at least one administration
Exclusion Criteria:
- Current RA functional status class IV according to the ACR 1991 revised criteria
•Previous use of secukinumab or other biologic drug directly targeting IL-17 or IL-17
receptor and/or any history of hypersensitivity to secukinumab or its excipient or to
drugs of similar chemical classes. Other protocol-defined inclusion/exclusion
criteria may apply
We found this trial at
26
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials